# Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis

> **NCT07249229** · PHASE2 · COMPLETED · sponsor: **Darya Chamani** · enrollment: 50 (actual)

## Conditions studied

- End-stage Renal Disease (ESRD)
- Hemodialysis

## Interventions

- **DRUG:** L-carnitine 1000 Mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07249229
- **Lead sponsor:** Darya Chamani
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-30
- **Primary completion:** 2021-02-28
- **Final completion:** 2021-03-08
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07249229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07249229, "Oral L-carnitine and Inflammatory and Nutritional Biomarkers in Maintenance Hemodialysis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07249229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*